Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Total Equity: ¥63,669 Mil (As of Mar. 2026)


SHSE:600196 Shanghai Fosun Pharmaceutical (Group) Co Ltd SHSE:600196
77 GF Score
Price ¥22.95
GF Value ¥27.13
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Shanghai Fosun Pharmaceutical (Group) Co Total Equity?

Shanghai Fosun Pharmaceutical (Group) Co SHSE:600196 77 Total Equity is ¥63,669 Mil as of Mar. 2026. GuruFocus rates SHSE:600196 with a GF Score™ of 77/100 and a GF Value™ of ¥27.13 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Shanghai Fosun Pharmaceutical (Group) Co's total equity for the quarter that ended in Mar. 2026 was ¥63,669 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Shanghai Fosun Pharmaceutical (Group) Co Total Equity Historical Data

* Premium members only.

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Total Equity Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48,379.57 54,108.91 56,616.26 59,933.73 61,840.35

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60,849.90 60,315.11 60,811.60 61,840.35 63,669.35
SHSE:600196
77GF Score
Shanghai Fosun Pharmaceutical (Group) Co Ltd SHSE:600196
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fosun Pharmaceutical (Group) Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Shanghai Fosun Pharmaceutical (Group) Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=120053.969-58213.619
=61,840

Shanghai Fosun Pharmaceutical (Group) Co's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=122966.388-59297.039
=63,669

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ¥63,669 Mil mean?
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) has a Total Equity of ¥63,669 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Shanghai Fosun Pharmaceutical (Group) Co and its competitors.
Is Shanghai Fosun Pharmaceutical (Group) Co's Total Equity too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Total Equity is ¥63,669 Mil. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Total Equity compare to ZTS and UTHR?
Shanghai Fosun Pharmaceutical (Group) Co's Total Equity of ¥63,669 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Shanghai Fosun Pharmaceutical (Group) Co and its competitors. Shanghai Fosun Pharmaceutical (Group) Co's current Total Equity is ¥63,669 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥27.13, compared to a current price of ¥22.95 — trading 15.4% below its estimated fair value. The current Total Equity is ¥63,669 Mil. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196), the current Total Equity is ¥63,669 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of ¥22.95 is trading 15.4% below its estimated GF Value™ of ¥27.13. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.

Key valuation signals for SHSE:600196:

  • Total Equity: ¥63,669 Mil
  • GF Value™: ¥27.13 vs. price of ¥22.95 (15.4% below fair value)
  • GF Score™: 77/100 with 10 warning signs

No single metric tells the full story. See the SHSE:600196 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
77GF Score

Get the complete analysis for SHSE:600196

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥22.95
Price
¥27.13
GF Value